Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Akorn gets tentative approval for eye product
Final approval is expected upon expiry of patent protection for Novartis' Voltaren Ophthalmic Solution in October 2007. Upon final approval, diclofenac sodium ophthalmic solution will be the generic
Final approval is expected upon expiry of patent protection for Novartis' Voltaren Ophthalmic Solution in October 2007. Upon final approval, diclofenac sodium ophthalmic solution will be the generic
Recent research has suggested that Tamiflu induces hallucinations and abnormal behavior, including self harm, in patients taking the antiviral drug Tamiflu. These reports include children and teenagers, primarily
Nycomed will have exclusive commercialization rights in Europe and other select countries, and Durect will retain full ownership of Posidur in the US, Canada, Asia and other countries.
In an 8-7 vote, with one abstention, panel members said that available data did not demonstrate that Celebrex was safe in treating the disease. However, the regulators decided
RVX-208 can rapidly increase plasma levels of ApoA-I up to 150% relative to control in animals in the first 24 hours. In previously announced studies, Resverlogix stated that
The results of the phase IIa trial found that EP-2104R was able to detect blood clots not previously seen on magnetic resonance imaging (MRI). Blood clots are a
This notification follows Progen's end-of-phase II meeting with the FDA. According to Progen, manufacturing the first step of PI-88 in-house saves Progen approximately AUD$7.8 million in outsourcing fees
The FDA and Avax have agreed on the trial design and endpoints under a special protocol assessment which will also expedite review of the product. “Our initial phase
This clinical trial was designed to investigate the safety, tolerability, pharmacokinetics and pharmacodynamic profile of a single dose of PTI-202 in healthy volunteers. Pain Therapeutics believes the results
Vioxx is from a class of drugs called Cox-2 inhibitors which block Cox-2 enzymes that are expressed in areas of inflammation, therefore targeting the site of pain. Vioxx